About our Team
Andrew X. Chen, PhD, RPh, President and Head of Research & Development
Andrew founded LATITUDE Pharmaceuticals Inc. in 2003 to address the increasingly difficult formulation challenges facing biotech and pharmaceutical companies. With over 20 years of formulation experience covering small molecule, peptide, protein, nucleic acid, and virus-based pharmaceuticals, Andrew’s deep experience enables LATITUDE to rapidly pinpoint key issues with difficult compounds and rapidly develop toxicology and commercial formulations for its clients. His formulations are behind one approved drug, two NDA-stage drugs, and numerous clinical and preclinical projects. Andrew’s creative and inventive approach has led to over 25 issued and pending formulation patents, many of which name him as the sole inventor. Recently, his contributions were recognized with over $1 million in grant funding from the Helmsley Charitable Trust and JDRF to develop new therapies for diabetes. Before founding LATITUDE, Andrew held positions of increasing responsibility at Bristol Myers Squibb Co., Immulogic, Inc., Selective Genetics, Inc., and IriSys, Inc. Andrew obtained his BS degree in pharmacy from Zhejiang University and his MS in PhD degrees in Pharmaceutical Sciences from St. John’s University in New York. Andrew is also a registered pharmacist.
Matthew A. Singer, PhD, Vice President, Head of Business Development
Matt has over 20 years of experience in research and business development in the life sciences, as well as the reagent and pharmaceutical industries. Prior to joining LATITUDE in 2015, Matt was a business development executive at Allele Biotechnology & Pharmaceuticals, Inc. and Stemgent, Inc., where he coordinated business development, licensing activities and strategic alliance management. Prior to his business development work, Matt held positions of increasing responsibility in an R&D leadership role at EMD Millipore and Exelixis Pharmaceuticals, Inc. Matt received his A.B. degree in Molecular Biophysics and Biochemistry from Yale University, and earned his doctorate in the field of Molecular Biology at the University of California, Berkeley.
Anna M. Ridenour, Director of Sales and Marketing
Anna has over 20 years of life sciences and biotechnology industry experience with vast knowledge of research models, discovery, pre-clinical and human clinical technology. Prior to joining LATITUDE in 2015, she held various positions of increasing responsibility in areas of administration and customer service, account management and field sales with global contract research organizations such as, Harlan Laboratories and Charles River Laboratories. In these positions, Anna was instrumental in achieving increased revenue year after year in her assigned territories. Most recently, she was the Associate Director for Business Development in Western US for Protea Biociences, Inc. Anna received her BS degree in Psychology from the University of Santo Tomas, Manila, Philippines.
Stephen Wu, General Manager and Head of Operations
Stephen has broad industry experience from covering accounting and management positions at financial institutions, large manufacturing companies, and R&D companies. Since joining LATITUDE in 2003, he has since served as the company’s General Manager, having responsibility for all aspects of LATITUDE’s accounting and administrative functions as well as the buildout and management of the company’s facilities and infrastructure.